Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease.

Alzheimer disease and associated disorders - 1 Jan 2000

Stonnington Cynthia M, Harel Brian, Locke Dona E C, Hentz Joseph G, Zhang Nan, Maruff Paul, Caselli Richard J

Abstract excerpt

INTRODUCTION: This study set out to clarify the differential acute cognitive impact of lorazepam based on varying genetic risk for Alzheimer disease. METHODS: Fifty-seven cognitively unimpaired individuals aged 51 to 88, genotyped according to apolipoprotein E (APOE) and translocase of outer mitochondrial membrane (40 homolog) poly-T lengths, completed cognitive testing before, 2.5 and 5 hours after receiving a 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alzheimer Disease

Share to Apolipoprotein E4

Share to Apolipoproteins E

Share to Cognition

Share to APOE gene

Share to Genotype

Source

Open in PubMed Open full text

Identifiers

PMID: 28582280
DOI: 10.1097/WAD.0000000000000200
PMCID: PMC5699956

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease.PMID 28582280Read ↗

Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.Semantic proximity Read ↗

Apolipoprotein E epsilon4 allele and lorazepam effects on memory in high-functioning older adults.Semantic proximity Read ↗

Perceptual discrimination of complex objects: APOE e4 gene-dose effects in mid-lifeSemantic proximity Read ↗

Longitudinal modeling of cognitive aging and the TOMM40 effect.Semantic proximity Read ↗

The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ε3/ε3 genotype.Semantic proximity Read ↗

TOMM40 '523 Genotype Distinguishes Patterns of Cognitive Improvement for Executive Function in APOEɛ3 Homozygotes.Semantic proximity Read ↗

APOE-specific Cognitive Effects of Levetiracetam in Mid-Age AdultsSemantic proximity Read ↗

The apolipoprotein E epsilon4 allele and memory performance in HIV-1 seropositive subjects: differences at baseline but not after acute oral lorazepam challenge.Semantic proximity Read ↗

ApoE allelic variability influences pupil response to cholinergic challenge and cognitive impairment.Semantic proximity Read ↗

Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.Semantic proximity Read ↗

Effects of acute lorazepam administration on aminergic activity in normal elderly subjects: relationship to performance effects and apolipoprotein genotype.Semantic proximity Read ↗

A TOMM40 poly-T variant modulates gene expression and is associated with vocabulary ability and decline in nonpathologic aging.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.